Marizyme(OTC) MRZM

Current Price$0.00

Market Cap$100.00

Since IPO (2010)-100%

5 Year-100%

1 Year-100%

1 Month+0%

Marizyme last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-01-26

Marizyme stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2025-10-02
1 month	+0%	USD 0.00	2025-10-02
3 month	+0%	USD 0.00	2025-10-02
Year to date	+0%	USD 0.00	2025-10-02
1 year	-100%	USD 0.05	2025-01-15
3 year	-100%	USD 0.29	2023-01-27
5 year	-100%	USD 3.10	2021-01-27
Since inception	-100%	USD 1.74	2010-05-03

Marizyme Financials at a Glance

Market Cap

$100.00

Revenue (TTM)

$183.42K

Net Income (TTM)

-$22.03M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

-5.84 (Low)

Dividend

$0.00

Beta (Volatility)

-5.84 (Low)

Price

$0.00

Volume

Open

$0.00

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Mar 5, 2026

Dividend

$0.00

Beta (Volatility)

-5.84 (Low)

Price

$0.00

Volume

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

Mar 5, 2026

MRZM News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Marizyme

Marizyme, Inc. is a life sciences company focused on developing and commercializing innovative medical technologies. The company specializes in products aimed at improving patient outcomes in various medical fields, including vascular surgery and chronic disease management.

Products and Services

DuraGraft: A single-application treatment for vascular surgeries
Krillase: A protease-based platform for treating severe wounds and burns
MATLOC: A digital lab-on-chip device for chronic kidney disease diagnosis

Growth Outlook

Expansion into chronic disease management with MATLOC technology
Ongoing development of Krillase for multiple therapeutic applications
Potential partnerships to enhance product distribution and market reach

Financial Highlights

Recent quarterly revenue of $0, indicating a focus on R&D investment
Trailing twelve months (TTM) net income of -$32.45 million, reflecting ongoing operational challenges
Cash and cash equivalents of $63,732 as of September 30, 2024, highlighting liquidity concerns

Marizyme, Inc. operates in the biotechnology sector, emphasizing innovative solutions for critical medical needs. The company's flagship product, DuraGraft, is designed to enhance vascular surgery outcomes, while the Krillase platform targets severe wounds and other medical conditions. The development of MATLOC represents a strategic move into digital health, aiming to address chronic kidney disease diagnostics. Despite facing financial challenges, including a significant net loss in recent quarters, Marizyme's commitment to research and development positions it for potential growth. The company is actively exploring partnerships to expand its market presence and leverage its innovative technologies. Investors may find interest in the company's unique product offerings and its focus on addressing unmet medical needs in the healthcare landscape.

AI Generated • Jul 6, 2026

Industry

Biotechnology

Sector

Health Care

Employees

CEO

David L. Barthel, MBA

Website

www.marizyme.com

Headquarters

Jupiter, FL 33458, US

MRZM Financials

Key Financial Metrics (TTM)

Gross Margin

36.99%

Operating Margin

-5278.10%

Net Income Margin

-10767.77%

Return on Equity

-1089.84%

Return on Capital

-211.76%

Return on Assets

-315.87%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$100.00

Shares Outstanding

131.79M

Volume

Avg. Volume

Financials (TTM)

Gross Profit

-$736.33K

Operating Income

-$26.61M

EBITDA

-$11.25M

Operating Cash Flow

-$3.84M

Capital Expenditure

$4.00

Free Cash Flow

-$3.84M

Cash & ST Invst.

$63.73K

Total Debt

$26.66M

Marizyme Performance Analysis

Marizyme annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2021	2021-12-31	USD 210,279	N/A
2022	2022-12-31	USD 233,485	11.0%
2023	2023-12-31	USD 645,810	176.6%

Marizyme sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2023-12-31	-17.1%
Q1	2024-03-31	-78.2%
Q2	2024-06-30	-100.0%
Q3	2024-09-30	N/A

Marizyme annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2021	2021-12-31	USD -0.31	N/A
2022	2022-12-31	USD -0.94	207.1%
2023	2023-12-31	USD -1.53	63.2%

Marizyme sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q4	2023-12-31	67.2%
Q1	2024-03-31	75.2%
Q2	2024-06-30	34.5%
Q3	2024-09-30	51.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q3 2024YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$210.78K

-261.5%

Gross Margin

0.00%

N/A

Market Cap

$100.00

N/A

Market Cap/Employee

$7.69

N/A

Employees

N/A

Net Income

-$1.96M

+94.0%

EBITDA

-$644.00K

+97.4%

Quarterly Fundamentals

Name

Q3 2024YOY CHG

Total Cash

$63.73K

-86.6%

Total Debt

$26.66M

+23.4%

Accounts Receivable

$37.88K

-52.0%

Inventory

$26.87K

-72.9%

Long Term Debt

$355.18K

-55.9%

Short Term Debt

$26.30M

+26.5%

Return on Assets

-3.16%

N/A

Return on Invested Capital

54.31%

N/A

Free Cash Flow

-$983.13K

+14.7%

Operating Cash Flow

-$983.13K

+14.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

BPTHBio-Path Holdings, Inc.

BPTHBio-Path Holdings, Inc.$0.04+0.00%

HALBHalberd Corporation

HALBHalberd Corporation$0.00+11.11%

EVFMEvofem Biosciences, Inc.

EVFMEvofem Biosciences, Inc.$0.01-4.76%

ISCOInternational Stem Cell Corporation

ISCOInternational Stem Cell Corporation$0.31+10.71%

BMNDFBiomind Labs Inc.

BMNDFBiomind Labs Inc.$0.05+0.00%

CAIHFChia Tai Enterprises International Limited

CAIHFChia Tai Enterprises International Limited$0.28+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NOKNokia

NOKNokia$9.10-0.06%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.42-0.04%

ONDSOndas

ONDSOndas$7.80-0.02%

SOFISoFi Technologies

SOFISoFi Technologies$16.46-0.01%

NUNu Holdings

NUNu Holdings$14.09-0.01%

FFord Motor Company

FFord Motor Company$14.37+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.48+0.07%

Questions About MRZM

What is the current price of Marizyme?

Marizyme is trading at $0.00 per share.

What is the 52-week range for Marizyme?

Over the past 52 weeks, Marizyme has traded between $0.00 and $0.00.

How much debt does Marizyme have?

As of the most recent reporting period, Marizyme reported total debt of $26.66M.

How much cash does Marizyme have on hand?

Marizyme reported $63.73K in cash and cash equivalents in its most recent financial results.

What is Marizyme’s dividend yield?

Marizyme does not currently have a dividend yield.

Marizyme(OTC) MRZM

Marizyme Financials at a Glance

MRZM News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Marizyme

MRZM Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Marizyme Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About MRZM

What is the current price of Marizyme?

What is the 52-week range for Marizyme?

How much debt does Marizyme have?

How much cash does Marizyme have on hand?

What is Marizyme’s dividend yield?

Premium Investing Services